CA2616196C - A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor - Google Patents
A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor Download PDFInfo
- Publication number
- CA2616196C CA2616196C CA2616196A CA2616196A CA2616196C CA 2616196 C CA2616196 C CA 2616196C CA 2616196 A CA2616196 A CA 2616196A CA 2616196 A CA2616196 A CA 2616196A CA 2616196 C CA2616196 C CA 2616196C
- Authority
- CA
- Canada
- Prior art keywords
- pyridin
- methyl
- quinolin
- pyrrolo
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70164105P | 2005-07-22 | 2005-07-22 | |
| US60/701,641 | 2005-07-22 | ||
| PCT/US2006/025377 WO2007018818A1 (en) | 2005-07-22 | 2006-06-29 | A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2616196A1 CA2616196A1 (en) | 2007-02-15 |
| CA2616196C true CA2616196C (en) | 2012-08-21 |
Family
ID=37450942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2616196A Expired - Fee Related CA2616196C (en) | 2005-07-22 | 2006-06-29 | A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7872020B2 (https=) |
| EP (1) | EP1910370B1 (https=) |
| JP (1) | JP5242391B2 (https=) |
| BR (1) | BRPI0613639A2 (https=) |
| CA (1) | CA2616196C (https=) |
| DK (1) | DK1910370T3 (https=) |
| ES (1) | ES2542425T3 (https=) |
| HR (1) | HRP20150474T1 (https=) |
| HU (1) | HUE025209T2 (https=) |
| IL (1) | IL188181A (https=) |
| MX (1) | MX2008001020A (https=) |
| PL (1) | PL1910370T3 (https=) |
| PT (1) | PT1910370E (https=) |
| RS (1) | RS53999B1 (https=) |
| SI (1) | SI1910370T1 (https=) |
| WO (1) | WO2007018818A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR081810A1 (es) | 2010-04-07 | 2012-10-24 | Bayer Cropscience Ag | Piridinilpirazoles biciclicos |
| AU2012281281B2 (en) * | 2011-07-13 | 2017-06-01 | Tiumbio Co., Ltd | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
| ES2791627T3 (es) | 2012-11-12 | 2020-11-05 | Inst Catalana Recerca Estudis Avancats | Métodos y kits para el pronóstico del cáncer colorrectal |
| PL2970890T3 (pl) | 2013-03-14 | 2020-11-16 | The Brigham And Women's Hospital, Inc. | Kompozycje i sposoby ekspansji i hodowli nabłonkowych komórek macierzystych |
| EP3189134A1 (en) | 2014-09-03 | 2017-07-12 | The Brigham and Women's Hospital, Inc. | Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss |
| US11786457B2 (en) | 2015-01-30 | 2023-10-17 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
| ES2918924T3 (es) | 2015-04-01 | 2022-07-21 | Rigel Pharmaceuticals Inc | Inhibidores de TGF-beta |
| US10669528B2 (en) | 2015-06-25 | 2020-06-02 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
| JP6856648B2 (ja) | 2015-12-15 | 2021-04-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃｘｃｒ４受容体アンタゴニスト |
| US11021687B2 (en) | 2016-01-08 | 2021-06-01 | The Brigham And Women's Hospital, Inc. | Production of differentiated enteroendocrine cells and insulin producing cells |
| US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
| US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| EP4049665B1 (en) | 2016-03-15 | 2025-03-12 | The Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
| US10604528B2 (en) | 2016-07-07 | 2020-03-31 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Galunisertib crystalline form, preparation method thereof and use thereof |
| JP2019534266A (ja) | 2016-10-14 | 2019-11-28 | 江蘇恒瑞医薬股▲ふん▼有限公司 | ５員ヘテロアリール環の架橋した環誘導体、その製造方法およびその医学的使用 |
| EP3562827A1 (en) | 2016-12-30 | 2019-11-06 | Frequency Therapeutics, Inc. | 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells |
| CN110582497B (zh) * | 2017-03-17 | 2022-03-11 | 杭州领业医药科技有限公司 | Galunisertib的晶型及其制备方法和药物组合物 |
| WO2018170724A1 (zh) | 2017-03-21 | 2018-09-27 | 杭州领业医药科技有限公司 | 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶，其制备方法和药物组合物 |
| WO2019042383A1 (zh) * | 2017-08-31 | 2019-03-07 | 苏州科睿思制药有限公司 | Galunisertib的晶型及其制备方法和用途 |
| WO2019105082A1 (zh) * | 2017-11-30 | 2019-06-06 | 苏州科睿思制药有限公司 | Galunisertib的晶型及其制备方法和用途 |
| WO2019137027A1 (zh) * | 2018-01-12 | 2019-07-18 | 苏州科睿思制药有限公司 | Galunisertib的晶型及其制备方法和用途 |
| CN112135613A (zh) | 2018-03-20 | 2020-12-25 | 西奈山伊坎医学院 | 激酶抑制剂化合物和组合物及使用方法 |
| US20210254006A1 (en) | 2018-06-06 | 2021-08-19 | Ideaya Biosciences, Inc. | Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds |
| JP2021533788A (ja) | 2018-08-17 | 2021-12-09 | フリークエンシー セラピューティクス インコーポレイテッド | Ｊａｇ−１を上方制御することにより有毛細胞を生成するための組成物及び方法 |
| US11617745B2 (en) | 2018-08-17 | 2023-04-04 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating FOXO |
| WO2020142485A1 (en) | 2018-12-31 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| CN115282280A (zh) * | 2022-08-12 | 2022-11-04 | 中国科学技术大学 | TGF-β1信号抑制剂的新用途 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| GB202309553D0 (en) | 2023-06-24 | 2023-08-09 | Ucl Business Ltd | Compostions and uses thereof |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK287857B6 (sk) * | 2001-05-24 | 2012-01-04 | Eli Lilly And Company | Novel pyrrole derivatives as pharmaceutical agents |
| AU2003298611A1 (en) | 2002-11-21 | 2004-06-18 | Eli Lilly And Company | Mixed lineage kinase modulators |
| UA80571C2 (en) * | 2002-11-22 | 2007-10-10 | Lilly Co Eli | Quinolinyl-pyrrolopyrazoles |
-
2006
- 2006-06-29 PT PT67742809T patent/PT1910370E/pt unknown
- 2006-06-29 US US11/995,938 patent/US7872020B2/en not_active Expired - Fee Related
- 2006-06-29 CA CA2616196A patent/CA2616196C/en not_active Expired - Fee Related
- 2006-06-29 BR BRPI0613639-7A patent/BRPI0613639A2/pt not_active Application Discontinuation
- 2006-06-29 SI SI200631924T patent/SI1910370T1/sl unknown
- 2006-06-29 EP EP20060774280 patent/EP1910370B1/en active Active
- 2006-06-29 MX MX2008001020A patent/MX2008001020A/es active IP Right Grant
- 2006-06-29 HR HRP20150474TT patent/HRP20150474T1/hr unknown
- 2006-06-29 ES ES06774280.9T patent/ES2542425T3/es active Active
- 2006-06-29 JP JP2008522796A patent/JP5242391B2/ja not_active Expired - Fee Related
- 2006-06-29 WO PCT/US2006/025377 patent/WO2007018818A1/en not_active Ceased
- 2006-06-29 RS RS20150319A patent/RS53999B1/sr unknown
- 2006-06-29 DK DK06774280.9T patent/DK1910370T3/en active
- 2006-06-29 PL PL06774280T patent/PL1910370T3/pl unknown
- 2006-06-29 HU HUE06774280A patent/HUE025209T2/en unknown
-
2007
- 2007-12-17 IL IL188181A patent/IL188181A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US20100120854A1 (en) | 2010-05-13 |
| HUE025209T2 (en) | 2016-03-29 |
| EP1910370B1 (en) | 2015-04-22 |
| JP2009502780A (ja) | 2009-01-29 |
| BRPI0613639A2 (pt) | 2012-02-22 |
| IL188181A0 (en) | 2008-03-20 |
| JP5242391B2 (ja) | 2013-07-24 |
| WO2007018818A1 (en) | 2007-02-15 |
| PT1910370E (pt) | 2015-06-30 |
| CA2616196A1 (en) | 2007-02-15 |
| EP1910370A1 (en) | 2008-04-16 |
| HRP20150474T1 (xx) | 2015-06-05 |
| SI1910370T1 (sl) | 2015-06-30 |
| RS53999B1 (sr) | 2015-10-30 |
| PL1910370T3 (pl) | 2015-09-30 |
| US7872020B2 (en) | 2011-01-18 |
| MX2008001020A (es) | 2008-03-25 |
| DK1910370T3 (en) | 2015-06-08 |
| ES2542425T3 (es) | 2015-08-05 |
| IL188181A (en) | 2014-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2616196C (en) | A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor | |
| EP3037424B1 (en) | Novel quinoline-substituted compound | |
| AU2016288204B2 (en) | Inhibitors of EGFR and methods of use thereof | |
| AU2015330506B2 (en) | EGFR inhibitor, and preparation and application thereof | |
| AU2008252380B2 (en) | Quinazolin-oxime derivatives as Hsp90 inhibitors | |
| JP2015180679A (ja) | ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形 | |
| EP2985277A1 (en) | Dipyrromethene crystal and method for manufacturing same | |
| SK9622000A3 (en) | Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas | |
| AU2008208801A1 (en) | Purine derivatives | |
| AU2012291041A1 (en) | Uracil derivative and use thereof for medical purposes | |
| HUE029343T2 (en) | Quinolylpyrrolo-pyrimidyl fused ring compounds and salts thereof | |
| CA3149846A1 (en) | Quinoline derivatives as protein kinase inhibitors | |
| CN111542522B (zh) | 可用作激酶抑制剂的被取代的吡唑并嘧啶 | |
| UA54449C2 (uk) | 3-заміщені похідні піридо[4',3':4,5]тієно[2,3-d]піримідину | |
| EP3434674B1 (en) | ((4-(2-oxoimidazolidine-1-yl)pyrimidin-2-yl)amine derivatives as mutant idh inhibitors for treating cancer | |
| CN112823159B (zh) | 一类具有激酶抑制活性的芳香杂环类化合物 | |
| CN117800953A (zh) | 一种2-芳香胺基嘧啶类化合物及其制备方法与应用 | |
| KR101859170B1 (ko) | 트리아졸 화합물 및 이의 용도 | |
| CN118251400A (zh) | Axl激酶抑制剂的盐、其制备方法和用途 | |
| WO2014020531A1 (en) | Imidazo[1,2-b]pyridazin-6-amine derivatives as kinase jak-2 inhibitors | |
| HK1256370B (en) | 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer | |
| HK1256370A1 (en) | 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer | |
| PL167014B1 (pl) | Sposób wytwarzania nowych pochodnych azolu |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20200831 |